Next Article in Journal
Marine Benthic Cyanobacteria Contain Apoptosis-Inducing Activity Synergizing with Daunorubicin to Kill Leukemia Cells, but not Cardiomyocytes
Previous Article in Journal
Excavatoids O and P, New 12-Hydroxybriaranes from the Octocoral Briareum excavatum
Article Menu

Export Article

Open AccessArticle
Mar. Drugs 2010, 8(10), 2647-2658; doi:10.3390/md8102647

Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis

Department of Internal Medicine V, Heidelberg University Clinics, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Received: 29 July 2010 / Revised: 24 September 2010 / Accepted: 12 October 2010 / Published: 13 October 2010
View Full-Text   |   Download PDF [118 KB, uploaded 24 February 2015]   |  

Abstract

Soft tissue sarcoma (STS) comprises a large variety of rare malignant tumors. Development of distant metastasis is frequent, even in patients undergoing initial curative surgery. Trabectedin, a tetrahydroisoquinoline alkaloid isolated from the Caribbean marine tunicate Ecteinascidia turbinata, was approved in 2007 for patients with advanced STS after failure of anthracyclines and ifosfamide, or for patients unsuited to receive these agents. In this study, we retrospectively analyzed 25 patients who had been treated with trabectedin at our institution between 2007 and 2010. The majority (72%) had been heavily pre-treated with ³2 previous lines of chemotherapy. Response assessed by conventional RECIST criteria was low, with only one patient achieving a partial remission (PR) and 10 stable disease (SD) after three cycles of treatment. However, median progression-free survival (PFS) and overall survival (OS) were significantly prolonged in this population compared to non-responders, with 7.7 months versus 2.1 months (p < 0.0001; HR 15.37, 95% CI 4.3 to 54.5) and 12.13 months versus 5.54 months (p = 0.0137; HR 3.7, 95% CI 1.3 to 10.5), respectively. PFS for all patients was 58% at three months and 37% at six months. Side effects, including neutropenia, elevation of liver transaminases/liver function tests, and nausea/vomiting, were usually mild and manageable. However, dose reductions due to side effects were necessary in five patients. We conclude that trabectedin is an effective and generally well tolerated treatment for STS even in a heavily pre-treated patient population.
Keywords: trabectedin; soft tissue sarcoma; metastatic; advanced; chemotherapy trabectedin; soft tissue sarcoma; metastatic; advanced; chemotherapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Schmitt, T.; Keller, E.; Dietrich, S.; Wuchter, P.; Ho, A.D.; Egerer, G. Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis. Mar. Drugs 2010, 8, 2647-2658.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top